261 related articles for article (PubMed ID: 20209060)
1. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.
Sommerfeld MR; Müller G; Tschank G; Seipke G; Habermann P; Kurrle R; Tennagels N
PLoS One; 2010 Mar; 5(3):e9540. PubMed ID: 20209060
[TBL] [Abstract][Full Text] [Related]
2. Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2.
Pierre-Eugene C; Pagesy P; Nguyen TT; Neuillé M; Tschank G; Tennagels N; Hampe C; Issad T
PLoS One; 2012; 7(7):e41992. PubMed ID: 22848683
[TBL] [Abstract][Full Text] [Related]
3. Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling.
Varewijck AJ; Yki-Järvinen H; Schmidt R; Tennagels N; Janssen JA
Diabetes; 2013 Jul; 62(7):2539-44. PubMed ID: 23569175
[TBL] [Abstract][Full Text] [Related]
4. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I.
Ciaraldi TP; Carter L; Seipke G; Mudaliar S; Henry RR
J Clin Endocrinol Metab; 2001 Dec; 86(12):5838-47. PubMed ID: 11739448
[TBL] [Abstract][Full Text] [Related]
5. Differences in metabolic and mitogenic signallingof insulin glargine and AspB10 human insulin in rats [corrected].
Tennagels N; Welte S; Hofmann M; Brenk P; Schmidt R; Werner U
Diabetologia; 2013 Aug; 56(8):1826-34. PubMed ID: 23653049
[TBL] [Abstract][Full Text] [Related]
6. Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel.
ter Braak B; Siezen CL; Kannegieter N; Koedoot E; van de Water B; van der Laan JW
Arch Toxicol; 2014 Apr; 88(4):953-66. PubMed ID: 24464500
[TBL] [Abstract][Full Text] [Related]
7. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.
Kurtzhals P; Schäffer L; Sørensen A; Kristensen C; Jonassen I; Schmid C; Trüb T
Diabetes; 2000 Jun; 49(6):999-1005. PubMed ID: 10866053
[TBL] [Abstract][Full Text] [Related]
8. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function.
Hartmann T; Overhagen S; Ouwens DM; Raschke S; Wohlfart P; Tennagels N; Wronkowitz N; Eckel J
Cardiovasc Diabetol; 2016 Jul; 15():96. PubMed ID: 27422524
[TBL] [Abstract][Full Text] [Related]
9. Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities.
Ciaraldi TP; Sasaoka T
Horm Metab Res; 2011 Jan; 43(1):1-10. PubMed ID: 20938889
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells.
Chisalita SI; Arnqvist HJ
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E896-901. PubMed ID: 14722023
[TBL] [Abstract][Full Text] [Related]
11. Metabolic effect and receptor signalling profile of a non-metabolisable insulin glargine analogue.
Werner U; Korn M; Schmidt R; Wendrich TM; Tennagels N
Arch Physiol Biochem; 2014 Oct; 120(4):158-65. PubMed ID: 25144413
[TBL] [Abstract][Full Text] [Related]
12. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes.
Bolli GB; Hahn AD; Schmidt R; Eisenblaetter T; Dahmen R; Heise T; Becker RH
Diabetes Care; 2012 Dec; 35(12):2626-30. PubMed ID: 23093664
[TBL] [Abstract][Full Text] [Related]
13. Mitogenic potency of insulin glargine.
Zełobowska K; Gumprecht J; Grzeszczak W
Endokrynol Pol; 2009; 60(1):34-9. PubMed ID: 19224503
[TBL] [Abstract][Full Text] [Related]
14. Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I.
Liefvendahl E; Arnqvist HJ
Horm Metab Res; 2008 Jun; 40(6):369-74. PubMed ID: 18393172
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10.
Hansen BF; Glendorf T; Hegelund AC; Lundby A; Lützen A; Slaaby R; Stidsen CE
PLoS One; 2012; 7(5):e34274. PubMed ID: 22590494
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin.
Wada T; Azegami M; Sugiyama M; Tsuneki H; Sasaoka T
Diabetes Res Clin Pract; 2008 Sep; 81(3):269-77. PubMed ID: 18585815
[TBL] [Abstract][Full Text] [Related]
17. IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts.
Eckardt K; May C; Koenen M; Eckel J
Diabetologia; 2007 Dec; 50(12):2534-43. PubMed ID: 17898992
[TBL] [Abstract][Full Text] [Related]
18. The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin.
Berti L; Kellerer M; Bossenmaier B; Seffer E; Seipke G; Häring HU
Horm Metab Res; 1998 Mar; 30(3):123-9. PubMed ID: 9566852
[TBL] [Abstract][Full Text] [Related]
19. Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor.
Yehezkel E; Weinstein D; Simon M; Sarfstein R; Laron Z; Werner H
Diabetologia; 2010 Dec; 53(12):2667-75. PubMed ID: 20835859
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of receptors for IGF-I and insulin; evidence for hybrid insulin/IGF-I receptor in human coronary artery endothelial cells.
Chisalita SI; Nitert MD; Arnqvist HJ
Growth Horm IGF Res; 2006 Aug; 16(4):258-66. PubMed ID: 16914341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
